Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

The S&P 500 and Nasdaq climbed due to positive earnings reports, despite uncertainties surrounding Trump's policies and ...

The S&P 500 and Nasdaq closed higher, while the Dow dropped during a volatile session. Investors focused on earnings reports ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The ...

The S&P 500 and the Nasdaq rose on Thursday, as investors sifted through several upbeat earnings reports while awaiting ...

Stay updated on the latest stock market trends and company earnings. Discover the impact of market gains and profit reports ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.